Emcure Pharmaceuticals Ltd
Presentation on Unaudited Financial Results for the quarter ended June 30, 2026
RESULTS
▲ Positive Development
LOW RISK
📅 Filed on BSE: 06 Aug 2026, 01:59 PM IST · BSE ID: b73aada4-8569-41e5-a0ee-5edf7b78418c
View Original BSE Filing (PDF)
💡
In Simple Terms
Emcure Pharmaceuticals increased its Q1 FY27 revenue by 22.8% and profit by 36.2%, driven by strong international sales.
🤖 AI Summary
- Emcure Pharmaceuticals reported Q1 FY27 Revenue from Operations of INR 25,804 Mn, an increase of 22.8% year-over-year.
- International business revenue grew 34.2% YoY to INR 14,851 Mn, accounting for 58% of total Q1 FY27 revenue.
- Domestic revenue for Q1 FY27 increased by 10.2% YoY to INR 10,953 Mn, reflecting resilient performance.
- Profit After Tax (PAT) for Q1 FY27 stood at INR 2,925 Mn, a 36.2% year-over-year growth with a PAT margin of 11.3%.
- Mr. Satish Mehta will take over as Chairman, and Mr. Samit Mehta is appointed COO of Emcure and CEO of Gennova Biopharmaceuticals.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Revenue from Operations (Q1 FY27)
25,804 INR Mn
22.8%
International Revenue (Q1 FY27)
14,851 INR Mn
34.2%
Domestic Revenue (Q1 FY27)
10,953 INR Mn
10.2%
EBITDA (Q1 FY27)
5,080 INR Mn
25.8%
EBITDA Margin (Q1 FY27)
19.7%
50bps
Profit After Tax (PAT) (Q1 FY27)
2,925 INR Mn
36.2%
PAT Margin (Q1 FY27)
11.3%
110bps
🏢 How This Affects the Company
The company's market position is strengthened by robust international growth, particularly in Europe, RoW, and Canada, alongside continued domestic segment expansion in CNS, women's health, and cardio-metabolics. Gennova Biopharmaceuticals becoming a wholly-owned subsidiary enhances the group's biologics and biosimilars capabilities.
Improved EBITDA margin by 50 bps to 19.7% and PAT margin by 110 bps to 11.3% reflect enhanced operating efficiency and profitability. The strong revenue growth directly contributes to increased earnings.
Management changes, including Mr. Samit Mehta's appointment as COO of Emcure and CEO of Gennova Biopharmaceuticals, aim to provide broader oversight of R&D, operations, and licensing activities, strengthening leadership and continuity.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this financial results presentation.
👤
Who Is Affected
All shareholders are affected by the company's financial performance and strategic leadership changes, which influence future business direction and profitability.
🔍
Management Signal
Management's decision to appoint new leadership and integrate Gennova Biopharmaceuticals signals a focus on enhancing institutional depth, operational oversight, and long-term value creation.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q2 FY27 results — monitor international and domestic revenue growth trends.
Updates on R&D pipeline — specifically developments in biologics and biosimilars.
Further details on the implementation of the five-year plan and value creation initiatives.
LOW RISK
The filing presents positive financial results and strategic leadership updates with no immediate concerns.
💡 Investor Takeaway
Emcure Pharmaceuticals reported Q1 FY27 Revenue from Operations of INR 25,804 Mn, a 22.8% YoY increase. International business revenue surged by 34.2% YoY to INR 14,851 Mn, while Profit After Tax (PAT) grew 36.2% YoY to INR 2,925 Mn, with PAT margin at 11.3%.
⚖️ Strengths & Concerns
✅ Positives
- Q1 FY27 Revenue from Operations increased by 22.8% year-over-year to INR 25,804 Mn, indicating strong business expansion.
- Profit After Tax (PAT) grew by 36.2% YoY to INR 2,925 Mn in Q1 FY27, with PAT margin improving by 110 bps to 11.3%.
⚠️ Concerns
- Gross Profit Margin in Q1 FY27 decreased by 340 bps year-over-year to 58.4%, down from 61.8% in Q1 FY26.
- International business revenue showed a quarter-over-quarter decline of -0.5% (to INR 14,851 Mn) compared to Q4 FY26 (INR 14,925 Mn).
📅 Company Track Record
No previous filings containing specific financial or operational data for Emcure Pharmaceuticals Ltd. were found in the provided context.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Emcure Pharmaceuticals' Revenue from Operations in Q1 FY27?
Emcure Pharmaceuticals reported Revenue from Operations of INR 25,804 Mn for Q1 FY27, representing a 22.8% year-over-year increase.
What was the growth in Emcure Pharmaceuticals' International business revenue in Q1 FY27?
The International business revenue for Emcure Pharmaceuticals grew by 34.2% year-over-year to INR 14,851 Mn in Q1 FY27.
What was Emcure Pharmaceuticals' Profit After Tax (PAT) in Q1 FY27?
Emcure Pharmaceuticals reported a Profit After Tax (PAT) of INR 2,925 Mn for Q1 FY27, a 36.2% year-over-year increase.
What was Emcure Pharmaceuticals' EBITDA Margin in Q1 FY27?
Emcure Pharmaceuticals' EBITDA Margin for Q1 FY27 was 19.7%, an improvement of 50 bps compared to Q1 FY26.
What leadership changes were announced by Emcure Pharmaceuticals?
Mr. Satish Mehta will assume the role of Chairman in addition to his MD & CEO duties, and Mr. Samit Mehta has been appointed COO of Emcure Pharmaceuticals and CEO of Gennova Biopharmaceuticals.
Questions based on this BSE filing only. For information purposes.